Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3

Abstract Background MicroRNAs are small non-coding RNAs with pivotal regulatory functions in multiple cellular processes. Their significance as molecular predictors for breast cancer was demonstrated in the past 15 years. The aim of this study was to elucidate the role of hsa-miR-3651 for predicting of local control (LC) in early breast cancer. Results By means of high-throughput technology, hsa-miR-3651 was found to be differentially expressed between patients who experienced local relapse compared to those without (N = 23; p = 0.0035). This result could be validated in an independent cohort of 87 patients using RT-qPCR (p < 0.0005). In a second analysis step with a chip-based microarray containing 70,523 probes of potential target molecules, FERM domain protein 3 (FRMD3) was found to be the most down-regulated protein (N = 21; p = 0.0016). Computational analysis employing different prediction algorithms revealed FRMD3 as a likely downstream target of hsa-miR-3651 with an 8mer binding site between the two molecules. This could be validated in an independent patient set (N = 20, p = 0.134). Conclusion The current study revealed that hsa-miR-3651 is a predictor of LC in early breast cancer via its putative target protein FRMD3. Since microRNAs interfere in multiple pathways, the results of this hypothesis generating study may contribute to the development of tailored therapies for breast cancer in the future.

Download Full-text

0-85. Role of radiotherapy in early breast cancer and the salvaging of patients with local relapse

The Breast ◽

10.1016/s0960-9776(97)90666-4 ◽

1997 ◽

Vol 6 (4) ◽

pp. 248 ◽

Cited By ~ 1

Author(s):

D. Spooner ◽

J.M. Morrison ◽

G.D. Oates ◽

D.J. Ellis ◽

M.J.R. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Local Relapse

Download Full-text

Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer

Genes ◽

10.3390/genes11121404 ◽

2020 ◽

Vol 11 (12) ◽

pp. 1404

Author(s):

Barbara Zellinger ◽

Ulrich Bodenhofer ◽

Immanuela A. Engländer ◽

Cornelia Kronberger ◽

Peter Strasser ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Local Control ◽

P Value ◽

Second Phase ◽

Clinical Report ◽

Two Phase ◽

Downstream Target ◽

Phase Study ◽

Target Molecules

Background: In order to characterize the various subtypes of breast cancer more precisely and improve patients selection for breast conserving therapy (BCT), molecular profiling has gained importance over the past two decades. MicroRNAs, which are small non-coding RNAs, can potentially regulate numerous downstream target molecules and thereby interfere in carcinogenesis and treatment response via multiple pathways. The aim of the current two-phase study was to investigate whether hsa-miR-375-signaling through RASD1 could predict local control (LC) in early breast cancer. Results: The patient and treatment characteristics of 81 individuals were similarly distributed between relapse (n = 27) and control groups (n = 54). In the pilot phase, the primary tumors of 28 patients were analyzed with microarray technology. Of the more than 70,000 genes on the chip, 104 potential hsa-miR-375 target molecules were found to have a lower expression level in relapse patients compared to controls (p-value < 0.2). For RASD1, a hsa-miR-375 binding site was predicted by an in silico search in five mRNA-miRNA databases and mechanistically proven in previous pre-clinical studies. Its expression levels were markedly lower in relapse patients than in controls (p-value of 0.058). In a second phase, this finding could be validated in an independent set of 53 patients using ddPCR. Patients with enhanced levels of hsa-miR-375 compared to RASD1 had a higher probability of local relapse than those with the inverse expression pattern of the two markers (log-rank test, p-value = 0.069). Conclusion: This two-phase study demonstrates that hsa-miR-375/RASD1 signaling is able to predict local control in early breast cancer patients, which—to our knowledge—is the first clinical report on a miR combined with one of its downstream target proteins predicting LC in breast cancer.

Download Full-text

The role of chemotherapy in early breast cancer patients

Senologie - Zeitschrift für Mammadiagnostik und -therapie ◽

10.1055/s-2007-990338 ◽

2007 ◽

Vol 4 (03) ◽

Author(s):

T Čufer

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

Breast Cancer Patients

Download Full-text

Role of breast conservation surgery (BCS) and modified radical mastectomy (MRM) in early breast cancer - A comparative study

Medpusle International Journal of Surgery ◽

10.26611/1061125 ◽

2019 ◽

Vol 11 (2) ◽

pp. 112-116

Author(s):

Bhupendra Jayant Patil ◽

◽

Shital M Dikle ◽

Keyword(s):

Breast Cancer ◽

Comparative Study ◽

Early Breast Cancer ◽

Breast Conservation ◽

Radical Mastectomy ◽

Breast Conservation Surgery ◽

Modified Radical Mastectomy ◽

Conservation Surgery

Download Full-text

Dysregulation of HOX as a Potential Therapeutic Target in Breast Cancer

Current Medicinal Chemistry ◽

10.2174/0929867327666201102115327 ◽

2020 ◽

Vol 27 ◽

Author(s):

Ji-Yeon Lee ◽

Myoung Hee Kim

Keyword(s):

Breast Cancer ◽

Hox Genes ◽

Therapeutic Potential ◽

Expression Patterns ◽

Genome Structure ◽

Control Cell ◽

Three Dimensional ◽

Cellular Processes ◽

Hox Protein

: HOX genes belong to the highly conserved homeobox superfamily, responsible for the regulation of various cellular processes that control cell homeostasis, from embryogenesis to carcinogenesis. The abnormal expression of HOX genes is observed in various cancers, including breast cancer; they act as oncogenes or as suppressors of cancer, according to context. In this review, we analyze HOX gene expression patterns in breast cancer and examine their relationship, based on the three-dimensional genome structure of the HOX locus. The presence of non-coding RNAs, embedded within the HOX cluster, and the role of these molecules in breast cancer have been reviewed. We further evaluate the characteristic activity of HOX protein in breast cancer and its therapeutic potential.

Download Full-text

The Role of lncRNA in the Development of Tumors, Including Breast Cancer

International Journal of Molecular Sciences ◽

10.3390/ijms22168427 ◽

2021 ◽

Vol 22 (16) ◽

pp. 8427

Author(s):

Beata Smolarz ◽

Anna Zadrożna-Nowak ◽

Hanna Romanowicz

Keyword(s):

Breast Cancer ◽

Breast Carcinoma ◽

Present Article ◽

Noncoding Rnas ◽

Long Noncoding Rnas ◽

Regulation Of Transcription ◽

Ribonucleic Acids ◽

Detailed Review ◽

Cellular Processes

Long noncoding RNAs (lncRNAs) are the largest groups of ribonucleic acids, but, despite the increasing amount of literature data, the least understood. Given the involvement of lncRNA in basic cellular processes, especially in the regulation of transcription, the role of these noncoding molecules seems to be of great importance for the proper functioning of the organism. Studies have shown a relationship between disturbed lncRNA expression and the pathogenesis of many diseases, including cancer. The present article presents a detailed review of the latest reports and data regarding the importance of lncRNA in the development of cancers, including breast carcinoma.

Download Full-text